On the road to iPS cell cardiovascular applications.
Timothy J
TJ
Kamp
Gary E
GE
Lyons
D000200:Action Potentials; D000818:Animals; D020013:Calcium Signaling; D019070:Cell Lineage; D054338:Cell Transdifferentiation / Q000235:genetics; D046528:Chimerism; D005347:Fibroblasts / Q000378:metabolism* / Q000648:ultrastructure; D018507:Gene Expression Regulation, Developmental; D006801:Humans; D000090062:Kruppel-Like Factor 4; D051741:Kruppel-Like Transcription Factors / Q000235:genetics / Q000378:metabolism; D009200:Myocardial Contraction; D032383:Myocytes, Cardiac / Q000378:metabolism* / Q000648:ultrastructure; D050814:Octamer Transcription Factor-3 / Q000235:genetics / Q000378:metabolism; D038081:Organogenesis; D039904:Pluripotent Stem Cells / Q000378:metabolism* / Q000648:ultrastructure; D016271:Proto-Oncogene Proteins c-myc / Q000378:metabolism; D055748:SOXB1 Transcription Factors / Q000235:genetics / Q000378:metabolism; D023822:Tissue Engineering / Q000639:trends
D000090062:Kruppel-Like Factor 4; D051741:Kruppel-Like Transcription Factors; D050814:Octamer Transcription Factor-3; C494173:POU5F1 protein, human; D016271:Proto-Oncogene Proteins c-myc; C527782:SOX2 protein, human; D055748:SOXB1 Transcription Factors